Cited by 163Acute Kidney Injury ResearchRenal Transplantation Outcomes and TreatmentsChronic Kidney Disease and Diabetes

The DOI matches its Crossref record; 37 of the 39 references it cites were found in a registry or an index.

Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

Broeders, Nilufer, Knoop, Christiane, Antoine, Martine, Tielemans, Christian, Abramowicz, Daniel·2000·Nephrology Dialysis Transplantation

DOI 10.1093/ndt/15.12.1993

Open this paper in CoChat — free account

Abstract

BACKGROUND: Some reports indicate that fibrates can induce renal dysfunction. However, the clinical characteristics of these episodes, and the respective nephrotoxicity of the four main fibrates used-namely, fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil-remain ill defined. METHODS: To better characterize this side-effect, we first reviewed the charts of 27 patients from our institution who developed an impairment of renal function during fibrate therapy. We next analysed the articles (n=24) that contained data on renal function in patients taking fibrates (n=2676). RESULTS: Among our 27 patients, 25 were on fenofibrate therapy, one was taking bezafibrate, and one ciprofibrate. Nineteen were recipients of solid-organ transplants (kidney recipients, n=15; heart or heart-lung recipients, n=4), and eight were non-transplanted patients with some impairment of renal function. Baseline plasma creatinine ranged from 0.9 to 2.9 mg/dl. It increased by a mean of 40% after the start of fibrate therapy. There was a concomitant increase of blood urea values (mean 36%) in most of the patients. Renal function returned to baseline in 18/24 patients after fibrate discontinuation. However, six patients, all transplant recipients, experienced a permanent increase in plasma creatinine. The incidence of fibrate-induced renal dysfunction among our series of kidney transplant recipients was 60%, as it occurred in 15 of the 25 patients who had ever taken fibrates. An increase of mean creatinine values during therapy was described in all papers on fenofibrate (n=7) and bezafibrate (n=8) (range 8-18% and 8-40% respectively), and in three of four papers dealing with ciprofibrate (range 6-16%). No significant renal impairment was described in any of the eight articles reporting data on gemfibrozil therapy. CONCLUSION: Therapy with fenofibrate, bezafibrate, and ciprofibrate may induce renal dysfunction. Gemfibrozil appears to be devoid of this side-effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/ndt/15.12.1993

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,638
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand Assay
Krey, G. D., Braissant, O., L’Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., & Wahli, W. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.6.0007 · Cited by 1,230
Plasma triglyceride and coronary heart disease
Austin, M. A. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.1.2 · Cited by 697 · cited 1×
“To better characterize this side-effect, we important risk factors for the development of atherofirst reviewed the charts of 27 patients from our sclerosis [1–3].”
Background
Biochemical Mechanisms Of Induction Of Hepatic Peroxisome Proliferation
Lock, E. A., Mitchell, A. M., & Elcombe, C. R. (1989) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.29.040189.001045 · Cited by 424
Hyperlipidemia in patients with chronic renal disease
Kasiske, B. L. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820472 · Cited by 283
Long-Term Efficacy and Safety of Fenofibrate and a Statin in the Treatment of Combined Hyperlipidemia
Ellen, R., & McPherson, R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00040-x · Cited by 175
Serum homocysteine increases after therapy with fenofibrate or bezafibrate
Dierkes, J., Westphal, S., & Luley, C. H. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02153-4 · Cited by 144

Show all 39 references

Research works printed but not linked: 2

Orö L, Carlson LA, Olsson A, Poole PH. Long‐term efficacy and safety of ciprofibrate in patients with primary hyperlipidemia. Curr Ther Res1992; 51: 750–762
de Gennes JL, Truffert J, Dairou F. Evaluation de l'activité hypolipidémiante et de la tolérance du ciprofibrate. Sem Hop1985; 61: 2807–2812

Sorted by citations

Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Estimation of Renal Function in Subjects With Normal Serum Creatinine Levels: Influence of Age and Body Mass Index
Verhave, J. C., Fesler, P., Ribstein, J., du Cailar, G., & Mimran, A. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.05.011 · Cited by 383
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
Kasiske, B. L., Cosío, B. G., Beto, J. A., Bolton, K., Chavers, B. M., Grimm, R. H., Levin, A., Masri, B. A., Parekh, R. S., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 313
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 281
New Fibrate Use and Acute Renal Outcomes in Elderly Adults: A Population-Based Study
Zhao, Y. Y., Weir, M. A., Manno, M., Cordy, P., Gomes, T., Hackam, D. G., Juurlink, D. N., Mamdani, M., Moist, L., Parikh, C. R., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-8-201204170-00401 · Cited by 258
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Effects of Fibrates in Kidney Disease
Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189
Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine
Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186
Metabolic syndrome and chronic kidney disease: Current status and future directions
Prasad, G. V. R. (2014) · World Journal of Nephrology · doi:10.5527/wjn.v3.i4.210 · Cited by 164
Effects of Fibrates on Serum Metabolic Parameters
Elisaf, M. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000516 · Cited by 163
Statin-fibrate combination therapy for hyperlipidaemia: a review
Wierzbicki, A. S., Mikhailidis, D. P., Wray, R., Schachter, M., Cramb, R., Simpson, W. G., & Byrne, C. D. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001668 · Cited by 156
Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
Mychaleckyj, J. C., Craven, T., Nayak, U., Buse, J., Crouse, J. R., Elam, M., Kirchner, K., Lorber, D., Marcovina, S., Sivitz, W., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1811 · Cited by 149
Effects of a Potent and Selective PPAR-α Agonist in Patients With Atherogenic Dyslipidemia or Hypercholesterolemia
Nissen, S. E., Nicholls, S. J., Wolski, K., Howey, D. C., McErlean, E. S., Wang, M.-D., Gomez, E. V., & Russo, J. (2007) · JAMA · doi:10.1001/jama.297.12.1362 · Cited by 133
Nondiabetic Kidney Disease
Levey, A. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp013462 · Cited by 126
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)
Committee for the Korean Guidelines for the Management of Dyslipidemia (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.3.275 · Cited by 123
The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy
Fazio, S., & Linton, M. F. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0104-8 · Cited by 118
False Estimates of Elevated Creatinine
Samra, M., & Abcar, A. C. (2012) · The Permanente Journal · doi:10.7812/tpp/11-121 · Cited by 115
The key role of altered tubule cell lipid metabolism in kidney disease development
Lee, L. E., Doke, T., Mukhi, D., & Suszták, K. (2024) · Kidney International · doi:10.1016/j.kint.2024.02.025 · Cited by 120
Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency
Tonelli, M. A., Collins, D. E., Robins, S. J., Bloomfield, H. E., & Curhan, G. C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00862.x · Cited by 105
Effects of fenofibrate and gemfibrozil on plasma homocysteine
Westphal, S., Dierkes, J., & Luley, C. H. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05271-5 · Cited by 99
Managing dyslipidemia in chronic kidney disease
Weiner, D. E., & Sarnak, M. J. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.40049.x · Cited by 94
Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People
Ansquer, J.-C., Dalton, R. N., Caussé, E., Crimet, D., Le Malicot, K., & Foucher, C. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.01.014 · Cited by 107
Fibrate Therapy
Remick, J. S., WEINTRAUB, H. S., Setton, R. A., Offenbacher, J., Fisher, E. A. A., & Schwartzbard, A. Z. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31816b43d3 · Cited by 83
Gemfibrozil, stretching arms beyond lipid lowering
Roy, A., & Pahan, K. (2009) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923970902785253 · Cited by 84
Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment
Wissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 83
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 86
Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management
Griffith, M. L., Savani, B. N., & Boord, J. B. (2010) · Blood · doi:10.1182/blood-2010-03-276576 · Cited by 82
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030706 · Cited by 79
Gout in Solid Organ Transplantation
Stamp, L. K., SEARLE, M., O???Donnell, J., & Chapman, P. T. (2005) · Drugs · doi:10.2165/00003495-200565180-00004 · Cited by 77
Fenofibrate: Metabolic and Pleiotropic Effects
Tsimihodimos, V., Miltiadous, G. A., Daskalopoulou, S. S., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Vascular Pharmacology · doi:10.2174/1570161052773942 · Cited by 74
Effect of tesaglitazar, a dual PPARα/γ agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12‐week dose-ranging trial
Goldstein, B. J., Rosenstock, J., Anzalone, D. A., Tou, C., & Öhman, K. P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x154169 · Cited by 70
Pharmacoepidemiology Safety Study of Fibrate and Statin Concomitant Therapy
Enger, C. L., Gately, R. V., Ming, E. E., Niemcryk, S. J., Williams, L. A., & McAfee, A. T. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.07.041 · Cited by 66
Fenofibrate and the kidney: an overview
Kostapanos, M. S., Florentin, M., & Elisaf, M. (2013) · European Journal of Clinical Investigation · doi:10.1111/eci.12068 · Cited by 65
Treatment of hyperlipidemia in cardiac transplant recipients
Bilchick, K. C., Henrikson, C. A., Skojec, D. V., Kasper, E. K., & Blumenthal, R. S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.050 · Cited by 66
Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials
Chan, D. T., Irish, A. B., Dogra, G. K., & Watts, G. F. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.01.023 · Cited by 65
Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
Bonds, D. E., Craven, T. E., Buse, J. B., Crouse, J. R., Cuddihy, R. M., Elam, M. B., Ginsberg, H. N., Kirchner, K. A., Marcovina, S. M., Mychaleckyj, J. C., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2524-2 · Cited by 64
2015 Korean Guidelines for Management of Dyslipidemia
Committee for Guidelines for Management of Dyslipidemia (2015) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2015.4.1.61 · Cited by 65
Fibrates: What Have We Learned in the Past 40 Years?
Backes, J. M., Gibson, C., Ruisinger, J. F., & Moriarty, P. M. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.412 · Cited by 63
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
Milionis, H. J., Moutzouri, E., Kei, & Elisaf, M. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5593 · Cited by 59
Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review
Τζιόμαλος, Κ., & Athyros, V. G. (2006) · International Journal of Nanomedicine · doi:10.2147/nano.2006.1.2.129 · Cited by 58
Fenofibrate-associated nephrotoxicity: A review of current evidence
Attridge, R. L., Frei, C. R., Ryan, L., Koeller, J. M., & Linn, W. D. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120131 · Cited by 57
Treatment of hyperlipidaemia with fenofibrate and related fibrates
Filippatos, T. D., & Milionis, H. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1599 · Cited by 57
Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease
Tonelli, M., Collins, D., Robins, S., Bloomfield, H., & Curhan, G. C. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)01082-0 · Cited by 56
Chronic treatment of curcumin improves hepatic lipid metabolism and alleviates the renal damage in adenine-induced chronic kidney disease in Sprague-Dawley rats
Ghelani, H., Razmovski‐Naumovski, V., Chang, D., & Nammi, S. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1621-6 · Cited by 57
Benefits and risks of the treatment with fibrates––a comprehensive summary
Okopień, B., Bułdak, Ł., & Bołdys, A. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1537780 · Cited by 55
Hyperlipidemia in kidney disease: causes and consequences
Sahadevan, M., & Kasiske, B. L. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200205000-00009 · Cited by 52
The pros and the cons of mTOR inhibitors in kidney transplantation
Ponticelli, C. E. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.872562 · Cited by 50
A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus
Bays, H. E., McElhattan, J., & Bryzinski, B. S. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.039 · Cited by 49
Diagnosis and Therapy of Coronary Artery Disease in Renal Failure, End-Stage Renal Disease, and Renal Transplant Populations
Beddhu, S., Logar, C. M., & Herzog, C. A. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200304000-00008 · Cited by 48
Fibrate treatment can increase serum creatinine levels
Tsimihodimos, V., Kakafika, A. I., & Elisaf, M. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.6.1301 · Cited by 47
Impact of treating the metabolic syndrome on chronic kidney disease
Agrawal, V., Shah, A., Rice, C., Franklin, B. A., & McCullough, P. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.114 · Cited by 62
Update on Fenofibrate
Guay, D. R. P. (2002) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2002.tb00098.x · Cited by 45
Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes
Wilding, J. P. H., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.040 · Cited by 44
Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.
Dierkes, J., Luley, C. H., & Westphal, S. (2007) · PubMed Central · Cited by 43
Beneficial Effect of Omega-3 Fatty Acids on Sirolimus- or Everolimus-Induced Hypertriglyceridemia in Heart Transplant Recipients
Celik, S., Doesch, A. O., Erbel, C., Blessing, E., Ammon, K., Koch, A., Katus, H. A., & Dengler, T. J. (2008) · Transplantation · doi:10.1097/tp.0b013e318177281e · Cited by 43
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels
Dierkes, J., Westphal, S., & Luley, C. H. (2004) · Expert Opinion on Drug Safety · doi:10.1517/eods.3.2.101.27336 · Cited by 40
Effects of high dose aleglitazar on renal function in patients with type 2 diabetes
Herz, M., Gaspari, F., Perico, N., Viberti, G. C., Urbanowska, T., Rabbia, M. A., & Kirk, D. A. W. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.037 · Cited by 39
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy
Štulc, T., Melenovský, V., Grauová, B., Kožich, V., & Češka, R. (2001) · Nutrition · doi:10.1016/s0899-9007(01)00612-8 · Cited by 37
Lipids, lipid-lowering therapy and diabetes complications
Valensi, P. E., & Picard, S. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.10.001 · Cited by 38
Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: Biopsy evidence of tubular toxicity
Angeles, C., LANE, B. P., Miller, F. W., & Nord, E. P. (2004) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.05.040 · Cited by 36
Comparison of Gemfibrozil and Fenofibrate in Patients with Dyslipidemic Coronary Heart Disease
Packard, K. A., Backes, J. M., Lenz, T. L., Wurdeman, R. L., Destache, C. J., & Hilleman, D. E. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.17.1527.34128 · Cited by 35
Effect of Ciprofibrate on Lipoproteins, Fibrinogen, Renal Function, and Hepatic Enzymes
Rizos, E. C., Bairaktari, E. T., Ganotakis, E. S., Tsimihodimos, V., Mikhailidis, D. P., & Elisaf, M. (2002) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840200700404 · Cited by 35
Effect of Fenofibrate Medication on Renal Function
Kim, S., Ko, K., Park, S., Lee, D. R., & Lee, J. (2017) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2017.38.4.192 · Cited by 34
Fibrate therapy and renal function
Sica, D. A. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0051-5 · Cited by 33
Prevention of Cardiovascular Disease Utilizing Fibrates-A Pooled Meta-analysis
Loomba, R. S., & Arora, R. R. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181dcf72b · Cited by 30
Treatment of dyslipidemia in kidney transplantation
Ponticelli, C. E., Arnaboldi, L., Moroni, G. L., & Corsini, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1732921 · Cited by 29
Antioxidant and Hypolipidemic Activity of the Hydroethanolic Extract of Curatella americana L. Leaves
Lopes, R. H., Macorini, L. F. B., Antunes, K. Á., Espindola, P. P. D. T., Monteiro‐Alfredo, T., da Rocha, P. D. S., Pereira, Z. V., dos Santos, E. L., & Souza, K. D. P. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/9681425 · Cited by 26
Fenofibrate-Induced Hyperhomocysteinaemia
Dierkes, J., Westphal, S., & Luley, C. H. (2003) · Drug Safety · doi:10.2165/00002018-200326020-00002 · Cited by 26
Fenofibrate-induced renal dysfunction, yes or no?
Nematbakhsh, M., Emami, F., Hariri, A., & Matinfar, M. (2020) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_772_19 · Cited by 24
Elevated serum creatinine levels associated with fenofibrate therapy
McQuade, C. R., Griego, J. E., Anderson, J. E., & Pai, A. B. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070005 · Cited by 25
Fibrates may Cause an Abnormal Urinary Betaine Loss Which is Associated with Elevations in Plasma Homocysteine
Lever, M., George, P. M., Slow, S., Elmslie, J. L., Scott, R. S., Richards, M., Fink, J., & Chambers, S. T. (2009) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-009-6188-1 · Cited by 24
Fibrates for treatment of the metabolic syndrome
Maki, K. C. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0115-5 · Cited by 24
The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes
Göke, B., Gause‐Nilsson, I. A. M., & Persson, A. (2007) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2007.041 · Cited by 24
Role of nuclear receptors, lipid metabolism, and mitochondrial function in the pathogenesis of diabetic kidney disease
Hughes, E. P., Wang, X. X., Sabol, L., Barton, K., Hegde, S., Myakala, K., Krawczyk, E., Rosenberg, A. Z., & Levi, M. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00110.2025 · Cited by 27
Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity
Attridge, R. L., Linn, W. D., Ryan, L., Koeller, J. M., & Frei, C. R. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.08.008 · Cited by 23
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Broeders, N., & Abramowicz, D. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00129.x · Cited by 22
Self-citation
Ameliorative potential of gemfibrozil and silymarin on experimentally induced nephrotoxicity in rats
Kabel, A. M., Mahmoud, H. A., & Kholy, S. S. E. (2013) · African Journal of Urology · doi:10.1016/j.afju.2013.04.002 · Cited by 21
Potentiation of TNF-α–Stimulated Group IIA Phospholipase A2 Expression by Peroxisome Proliferator–Activated Receptor α Activators in Rat Mesangial Cells
Scholz‐Pedretti, K., Gans, A., Beck, K., Pfeilschifter, J. M., & Kaszkin, M. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v133611 · Cited by 22
Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD
Hamed, A. M., El-Kharashi, O. A., Boctor, S. S. A., & Abd-Elaziz, L. F. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.114 · Cited by 20
Non-lipid effects of rosuvastatin–fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia
Lee, S., Cho, K. I., Kim, J., Ahn, Y. K., Rha, S., Kim, Y.-J., Choi, Y. S., Choi, S. W., Jeon, D. W., Min, P., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.042 · Cited by 20
Oral supplement of six selective amino acids arrest progression renal failure in uremic patients
Yatzidis, H. (2004) · International Urology and Nephrology · doi:10.1007/s11255-004-8782-2 · Cited by 20
Positive and negative false estimates of serum creatinine
Nigam, P. K., & Chandra, A. (2017) · Interventional Cardiology · doi:10.4172/interventional-cardiology.1000572 · Cited by 19
Tratamento das dislipidemias: como e quando indicar a combinação de medicamentos hipolipemiantes
Schulz, I. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200021 · Cited by 19
Hypolipidemic Drugs Can Change the Composition of Rat Brain Lipids
Vecka, M., TVRZICKÁ, E., Staňková, B., Novak, F. J., Nováková, O., & Žák, A. (2004) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.204.299 · Cited by 19
Fibrate‐induced increase in blood urea and creatinine
Lipscombe, J., & Bargman, J. M. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.7.1515 · Cited by 19
Gout and Organ Transplantation
Stamp, L. K., & Chapman, P. T. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-012-0235-9 · Cited by 18
A Dual PPAR ??/?? Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects
Decochez, K., Rippley, R. K., Miller, J., Smet, M. D., Yan, K. X., Mathijs, Z., Riffel, K. A., Song, H., Zhu, H., Maynor, H. O., et al. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00004 · Cited by 17
Fibrate therapy in patients with metabolic syndrome and diabetes mellitus
Dayspring, T. D., & Pokrywka, G. S. (2006) · Current Atherosclerosis Reports · doi:10.1007/s11883-006-0032-x · Cited by 16
Fibrate‐induced increase in serum urea and creatinine levels
Tsimihodimos, V., Bairaktari, E. T., & Elisaf, M. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.4.682 · Cited by 16
Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study
Hyun, Y. Y., Kim, K., Hong, S., Han, K., & Park, C. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15815 · Cited by 14
[Fibrate-induced deterioration of renal function].
Polanco, N. A., Hernández, E., González, E., Martínez, E. G., Bello, I., Gutierrez‐Millet, V., García, F., Morales, E., & Praga, M. (2009) · PubMed · doi:10.3265/nefrologia.2009.29.3.5152.en.full · Cited by 15
The triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation
Anderson, J. L. C., Bakker, S. J. L., & Tietge, U. J. F. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.01.009 · Cited by 15
Bezafibrates Cause Moderate, Reversible Impairment in Renal Function in Patients without Prior Renal Disease
Charach, G., Grosskopf, I., Rotmensch, H. H., Kitzis, I., & Weintraub, M. S. (2005) · Nephron Clinical Practice · doi:10.1159/000085291 · Cited by 13
Dyslipidemia in patients with chronic kidney disease: etiology and management.
Dušejovská, M., Vecka, M., Rychlík, I., & Žák, A. (2020) · Vnitrni lekarstvi · doi:10.36290/vnl.2020.082 · Cited by 17
The dual peroxisome proliferator–activated receptor α/γ agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin
Tonstad, S., Retterstøl, K., Ose, L., Öhman, K. P., Lindberg, M. B., & Svensson, M. K. E. (2007) · Metabolism · doi:10.1016/j.metabol.2007.05.003 · Cited by 12
Diabetes and other endocrine-metabolic abnormalities in the long-term follow-up of pancreas transplantation
Lauria, M. W., & Ribeiro‐Oliveira, A. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0032-x · Cited by 11
Does lipid-lowering therapy slow progression of chronic kidney disease?
Wheeler, D. C. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)01139-4 · Cited by 11
Alkaline N-GQDs fluorescent probe for the ultrasensitive detection of creatinine
Ravi, P. V., Subramaniyam, V., Saravanakumar, N., & Pichumani, M. (2022) · Methods and Applications in Fluorescence · doi:10.1088/2050-6120/ac8527 · Cited by 10

Authors: Broeders, N., Knoop, C., Antoine, M., Tielemans, C., & Abramowicz, D.
Affiliations: Erasmus Hospital (BE)
ORCID: Knoop, Christiane
Abramowicz, Daniel
Venue: Nephrology Dialysis Transplantation
Publisher: Oxford University Press (OUP)
Published: 2000-12-01
Volume: 15
Issue: 12
Pages: 1993-1999
ISSN: 0931-0509 (ISSN-L)
1460-2385
DOI: 10.1093/ndt/15.12.1993
OpenAlex: W2099822840
Cited by: 163
References: 39
Citations by year: 2026: 3 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 8 · 2013: 7 · 2012: 8
FWCI: 5.96
Type: journal article
Language: en
Open access: closed
Locations: Nephrology Dialysis Transplantation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords: fibrates, nephrotoxicity, renal dysfunction, gemfibrozil, fenofibrate, bezafibrate, ciprofibrate, blood urea, serum creatinine, kidney transplant recipients, drug-induced nephrotoxicity
MeSH terms: Hypolipidemic Agents, Bezafibrate, Clofibric Acid, Creatinine, Humans, Kidney Diseases, Postoperative Period, Fenofibrate, Retrospective Studies, Urea, Gemfibrozil, Kidney Transplantation, Fibric Acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fibrate‐induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks